141 related articles for article (PubMed ID: 24950792)
1. Combined analysis of biomarkers of proliferation and apoptosis in colon cancer: an immunohistochemistry-based study using tissue microarray.
Reimers MS; Zeestraten EC; van Alphen TC; Dekker JW; Putter H; Saadatmand S; Liefers GJ; van de Velde CJ; Kuppen PJ
Int J Colorectal Dis; 2014 Sep; 29(9):1043-52. PubMed ID: 24950792
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
[TBL] [Abstract][Full Text] [Related]
3. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
4. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
6. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative fibrinogen in patients with colon cancer.
Sun ZQ; Han XN; Wang HJ; Tang Y; Zhao ZL; Qu YL; Xu RW; Liu YY; Yu XB
World J Gastroenterol; 2014 Jul; 20(26):8583-91. PubMed ID: 25024612
[TBL] [Abstract][Full Text] [Related]
9. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
10. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
11. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.
Mesker WE; Junggeburt JM; Szuhai K; de Heer P; Morreau H; Tanke HJ; Tollenaar RA
Cell Oncol; 2007; 29(5):387-98. PubMed ID: 17726261
[TBL] [Abstract][Full Text] [Related]
12. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value and initial exploratory research on TNM staging method of tumor deposits in stage III colon cancer].
Qin Q; Yang L; Zhou AP; Wang JW; Zhong DS
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1152-1158. PubMed ID: 31874531
[No Abstract] [Full Text] [Related]
15. Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
Dedić Plavetić N; Jakić-Razumović J; Kulić A; Sirotković-Skerlev M; Barić M; Vrbanec D
Pathol Oncol Res; 2015 Apr; 21(2):315-24. PubMed ID: 25096394
[TBL] [Abstract][Full Text] [Related]
16. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression?
Fernández-Cebrián JM; Nevado Santos M; Vorwald Kuborn P; Pardo de Lama M; Martín-Cavanna J; Pacheco Martínez P; Fernández Escudero B; Ramos Fernández M
Clin Transl Oncol; 2007 Oct; 9(10):663-70. PubMed ID: 17974527
[TBL] [Abstract][Full Text] [Related]
17. Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M; Belt EJ; Delis-van Diemen PM; Carvalho B; Coupé VM; Stockmann HB; Bril H; Beliën JA; Fijneman RJ; Meijer GA
Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S348-59. PubMed ID: 22711178
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature.
Gkekas I; Novotny J; Pecen L; Strigård K; Palmqvist R; Gunnarsson U
Anticancer Res; 2017 Dec; 37(12):6563-6574. PubMed ID: 29187431
[TBL] [Abstract][Full Text] [Related]
19. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in sporadic colon cancer with high-level microsatellite instability.
Oh BY; Huh JW; Park YA; Cho YB; Yun SH; Kim HC; Lee WY; Chun HK
Surgery; 2016 May; 159(5):1372-81. PubMed ID: 26775578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]